Recombinant plasma proteins

Vox Sanguinis

Volumn 100, Issue 1, 2011, Pages 68-83

  Burnouf, T ^a  

^a HUMAN PROTEIN PROCESS SCIENCES   (France)

Author keywords

Plasma; Proteins; Recombinant

Indexed keywords

ACTIVATED PROTEIN C; ADALIMUMAB; ALBUMIN; ALPHA 1 ANTITRYPSIN; ANTITHROMBIN; BASILIXIMAB; BLOOD CLOTTING FACTOR; CERTOLIZUMAB PEGOL; COMPLEMENT COMPONENT C1S INHIBITOR; DACLIZUMAB; EFALIZUMAB; FIBRINOGEN; GOLIMUMAB; GREENGENE; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; MOTAVIZUMAB; NATALIZUMAB; PALIVIZUMAB; PROTEINASE INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT PROTEIN; RITUXIMAB; TGN 1412; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VON WILLEBRAND FACTOR;

AFIBRINOGENEMIA; BACULOVIRUS EXPRESSION SYSTEM; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD CLOTTING FACTOR DEFICIENCY; DISSEMINATED INTRAVASCULAR CLOTTING; ESCHERICHIA COLI; FUNGUS; GENE EXPRESSION SYSTEM; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOMODULATION; INFECTION; INFLAMMATORY DISEASE; INSECT CELL; MAMMAL CELL; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; RHEUMATIC DISEASE; TRANSGENIC ANIMAL; TRANSGENIC PLANT; VIRUS INFECTION; VON WILLEBRAND DISEASE; YEAST;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; BLOOD PROTEINS; CELL CULTURE TECHNIQUES; DNA, RECOMBINANT; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN G; PLANTS, GENETICALLY MODIFIED; PROTEASE INHIBITORS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 78650355088     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2010.01384.x     Document Type: Review

References (138)

1. Cohn E, Strong L, Hughes W, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946; 68:459-475
2. Burnouf T: Modern plasma fractionation. Transfus Med Rev 2007; 21:101-117
3. Burnouf T: [Plasma fractionation in the world: current status.]. Transfus Clin Biol 2007; 14:41-50
4. Farrugia A, Robert P: Plasma protein therapies: current and future perspectives. Best Pract Res Clin Haematol 2006; 19:243-258
5. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312:330-337
6. Kurachi K, Davie EW: Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci U S A 1982; 79:6461-6464
7. Pipe SW: Recombinant clotting factors. Thromb Haemost 2008; 99:840-850
8. Schirrmann T, Al-Halabi L, Dubel S, et al. Production systems for recombinant antibodies. Front Biosci 2008; 13:4576-4594
9. Demain AL, Vaishnav P: Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv 2009; 27:297-306
10. Ferrer-Miralles N, Domingo-Espin J, Corchero JL, et al. Microbial factories for recombinant pharmaceuticals. Microb Cell Fact 2009; 8:17
11. Ni Y, Chen R: Extracellular recombinant protein production from Escherichia coli. Biotechnol Lett 2009; 31:1661-1670
12. Brondyk WH: Selecting an appropriate method for expressing a recombinant protein. Methods Enzymol 2009; 463:131-147
13. Karnaukhova E, Ophir Y, Golding B: Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use. Amino Acids 2006; 30:317-332
14. Weidner M, Taupp M, Hallam SJ: Expression of recombinant proteins in the methylotrophic yeast Pichia pastoris. J Vis Exp 2010; 36: doi: 10.3791/1862
15. Porro D, Branduardi P: Yeast cell factory: fishing for the best one or engineering it? Microb Cell Fact 2009; 8:51
16. Kobayashi K: Summary of recombinant human serum albumin development. Biologicals 2006; 34:55-59
17. Nevalainen KM, Te'o VS, Bergquist PL: Heterologous protein expression in filamentous fungi. Trends Biotechnol 2005; 23:468-474
18. Nagaya H: Recombinant protein production by a Kaiko-baculovirus system. Methods Mol Biol 2009; 577:109-120
19. Hitchman RB, Possee RD, King LA: Baculovirus expression systems for recombinant protein production in insect cells. Recent Pat Biotechnol 2009; 3:46-54
20. Chu L, Robinson DK: Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 2001; 12:180-187
21. Pipe SW: The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost 2005; 3:1692-1701
22. Wurm FM: Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004; 22:1393-1398
23. Grillberger L, Kreil TR, Nasr S, et al. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 2009; 4:186-201
24. Houdebine LM: Transgenic animal bioreactors. Transgenic Res 2000; 9:305-320
25. Van Cott KE, Monahan PE, Nichols TC, et al. Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide. Haemophilia 2004; 10(Suppl 4):70-76
26. Echelard Y, Ziomek C, Meade HM: Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals. Biopharm Int 2006; 19(8):36-46
27. Niemann H, Kues WA: Transgenic farm animals: an update. Reprod Fertil Dev 2007; 19(8):762-770
28. Lienard D, Sourrouille C, Gomord V, et al. Pharming and transgenic plants. Biotechnol Annu Rev 2007; 13:115-147
29. Hellwig S, Drossard J, Twyman RM, et al. Plant cell cultures for the production of recombinant proteins. Nat Biotechnol 2004; 22:1415-1422
30. Spok A, Twyman RM, Fischer R, et al. Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants. Trends Biotechnol 2008; 26:506-517
31. Plasson C, Michel R, Lienard D, et al. Production of recombinant proteins in suspension-cultured plant cells. Methods Mol Biol 2009; 483:145-161
32. Ko K, Brodzik R, Steplewski Z: Production of antibodies in plants: approaches and perspectives. Curr Top Microbiol Immunol 2009; 332:55-78
33. Kaufman RJ, Wasley LC, Furie BC, et al. Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 1986; 261:9622-9628
34. White GC II, Beebe A, Nielsen B: Recombinant factor IX. Thromb Haemost 1997; 78:261-265
35. Shapiro AD, Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105:518-525
36. White G, Shapiro A, Ragni M, et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35:33-38
37. Lisauskas SF, Cunha NB, Vianna GR, et al. Expression of functional recombinant human factor IX in milk of mice. Biotechnol Lett 2008; 30:2063-2069
38. Zhang H, Zhao L, Chen Y, et al. Expression of human coagulation Factor IX in transgenic tomato (Lycopersicon esculentum). Biotechnol Appl Biochem 2007; 48:101-107
39. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312:326-330
40. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature 1984; 312:337-342
41. Burnouf T, Radosevich M: Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000; 14:94-110
42. Eaton DL, Hass PE, Riddle L, et al. Characterization of recombinant human factor VIII. J Biol Chem 1987; 262:3285-3290
43. Mei B, Chen Y, Chen J, et al. Expression of human coagulation factor VIII in a human hybrid cell line, HKB11. Mol Biotechnol 2006; 34:165-178
44. Burnouf T, Padilla A: Current strategies to prevent transmission of prions by human plasma derivatives. Transfus Clin Biol 2006; 13:320-328
45. Farrugia A, Evers T, Falcou PF, et al. Plasma fractionation issues. Biologicals 2009; 37:88-93
46. Cheraghali AM, Abolghasemi H: Plasma fractionation, a useful means to improve national transfusion system and blood safety: Iran experience. Haemophilia 2009; 15:487-493
47. Thim L, Vandahl B, Karlsson J, et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 2010; 16:349-359
48. Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116:270-279
49. Hermeling S, Crommelin DJ, Schellekens H, et al. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004; 21:897-903
50. Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107:46-51
51. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously-untreated hemophilia a patients treated with plasma-derived or recombinant factor VIII concentrates. A systematic review. J Thromb Haemost 2010; 8:1256-1265
52. Qadura M, Waters B, Burnett E, et al. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood 2009; 114:871-880
53. Chalmers EA, Brown SA, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13:149-155
54. Behrmann M, Pasi J, Saint-Remy JM, et al. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88:221-229
55. Gouw SC, van der Bom JG, Auerswald G, et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109:4693-4697
56. Lusher JM: Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000; 26:179-188
57. Hedner U: Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124:747-757
58. Tomokiyo K, Yano H, Imamura M, et al. Large-scale production and properties of human plasma-derived activated Factor VII concentrate. Vox Sang 2003; 84:54-64
59. Weiskopf RB: Recombinant-activated coagulation factor VIIa (NovoSeven): current development. Vox Sang 2007; 92:281-288
60. De Meyer SF, Deckmyn H, Vanhoorelbeke K: von Willebrand factor to the rescue. Blood 2009; 113:5049-5057
61. Schramm W: Haemate (R) P von Willebrand factor/factor VIII concentrate: 25-years of clinical experience. Haemophilia 2008; 14:3-10
62. Stadler M, Gruber G, Kannicht C, et al. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate). Biologicals 2006; 34:281-288
63. Burnouf-Radosevich M, Burnouf T: Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate. Vox Sang 1992; 62:1-11
64. Turecek PL, Mitterer A, Matthiessen HP, et al. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie 2009; 29(Suppl 1):S32-S38
65. Plaimauer B, Schlokat U, Turecek PL, et al. Recombinant von Willebrand factor: preclinical development. Semin Thromb Hemost 2001; 27:395-403
66. Lee HG, Lee HC, Kim SW, et al. Production of recombinant human von Willebrand factor in the milk of transgenic pigs. J Reprod Dev 2009; 55:484-490
67. Mosesson MW, Siebenlist KR, Meh DA: The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936:11-30
68. Townsend RR, Hilliker E, Li YT, et al. Carbohydrate structure of human fibrinogen. Use of 300-MHz 1H-NMR to characterize glycosidase-treated glycopeptides. J Biol Chem 1982; 257:9704-9710
69. Jackson MR, MacPhee MJ, Drohan WN, et al. Fibrin sealant: current and potential clinical applications. Blood Coagul Fibrinolysis 1996; 7:737-746
70. Radosevich M, Goubran HA, Burnouf T: Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sang 1997; 72:133-143
71. Mintz PD, Mayers L, Avery N, et al. Fibrin sealant: clinical use and the development of the University of Virginia Tissue Adhesive Center. Ann Clin Lab Sci 2001; 31:108-118
72. Tojo N, Miyagi I, Miura M, et al. Recombinant human fibrinogen expressed in the yeast Pichia pastoris was assembled and biologically active. Protein Expr Purif 2008; 59:289-296
73. Butler SP, O'Sickey TK, Lord ST, et al. Secretion of recombinant human fibrinogen by the murine mammary gland. Transgenic Res 2004; 13:437-450
74. Butler SP, van Cott K, Subrumanian A, et al. Current progress in the production of recombinant human fibrinogen in the milk of transgenic animals. Thromb Haemost 1997; 78:537-542
75. Mann KG, Butenas S, Brummel K: The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23:17-25
76. Ratner M: Recombinant thrombin approved. Nat Biotechnol 2008; 26:250
77. Aizawa P, Winge S, Karlsson G: Large-scale preparation of thrombin from human plasma. Thromb Res 2008; 122:560-567
78. Cheng CM, Meyer-Massetti C, Kayser SR: A review of three stand-alone topical thrombins for surgical hemostasis. Clin Ther 2009; 31:32-41
79. Clark J, Crean S, Reynolds MW: Topical bovine thrombin and adverse events: a review of the literature. Curr Med Res Opin 2008; 24:2071-2087
80. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997; 389:498-501
81. Semple E, Madsen T, Semple JW: Quality of thrombin produced from the patient's own plasma using the TPD, a new Thrombin-processing Device. J Extra Corpor Technol 2005; 37:196-200
82. Bishop PD, Lewis KB, Schultz J, et al. Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin. Semin Thromb Hemost 2006; 32(Suppl 1):86-97
83. Anderson CD, Bowman LJ, Chapman WC: Topical use of recombinant human thrombin for operative hemostasis. Expert Opin Biol Ther 2009; 9:133-137
84. Ballard JL, Weaver FA, Singla NK, et al. Safety and immunogenicity observations pooled from eight clinical trials of recombinant human thrombin. J Am Coll Surg 2010; 210:199-204
85. Crystal RG: Alpha 1-antitrypsin deficiency: pathogenesis and treatment. Hosp Pract (Off Ed) 1991; 26:81-84, 8-9, 93-4
86. Modrykamien A, Stoller JK: Alpha-1 antitrypsin (AAT) deficiency - what are the treatment options? Expert Opin Pharmacother 2009; 10:2653-2661
87. Mazereeuw-Hautier J, Cope J, Ong C, et al. Topical recombinant alpha1-antitrypsin: a potential treatment for Netherton syndrome? Arch Dermatol 2006; 142:396-398
88. Spencer LT, Humphries JE, Brantly ML: Antibody response to aerosolized transgenic human alpha1-antitrypsin. N Engl J Med 2005; 352:2030-2031
89. Roemisch J, Gray E, Hoffmann JN, et al. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13:657-670
90. Rodgers GM: Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency An update. Thromb Haemost 2009; 101:806-812
91. Maclean PS, Tait RC: Hereditary and acquired antithrombin deficiency - Epidemiology, pathogenesis and treatment options. Drugs 2007; 67:1429-1440
92. Ohya T, Hayashi T, Kiyama E, et al. Improved production of recombinant human antithrombin III in Chinese hamster ovary cells by ATF4 overexpression. Biotechnol Bioeng 2008; 100:317-324
93. Adiguzel C, Iqbal O, Demir M, et al. European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats. Clin Appl Thromb Hemost 2009; 15:645-651
94. Berry LR, Thong B, Chan AK: Comparison of recombinant and plasma-derived antithrombin biodistribution in a rabbit model. Thromb Haemost 2009; 102:302-308
95. Caliezi C, Wuillemin WA, Zeerleder S, et al. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000; 52:91-112
96. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139:379-394
97. Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009; 15:69-78
98. Dreyfus M, Ladouzi A, Chambost H, et al. Treatment of inherited protein C deficiency by replacement therapy with the French purified plasma-derived protein C concentrate (PROTEXEL). Vox Sang 2007; 93:233-240
99. Orthner CL, Ralston AH, Gee D, et al. Large-scale production and properties of immunoaffinity-purified human activated protein C concentrate. Vox Sang 1995; 69:309-318
100. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
101. Tarelli E, Mire-Sluis A, Tivnann HA, et al. Recombinant human albumin as a stabilizer for biological materials and for the preparation of international reference reagents. Biologicals 1998; 26:331-346
102. WHO: Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products. Geneva, WHO, 2003
103. Chuang VT, Otagiri M: Recombinant human serum albumin. Drugs Today (Barc) 2007; 43:547-561
104. Kobayashi K, Kuwae S, Ohya T, et al. High-level expression of recombinant human serum albumin from the methylotrophic yeast Pichia pastoris with minimal protease production and activation. J Biosci Bioeng 2000; 89:55-61
105. Kobayashi K, Nakamura N, Sumi A, et al. The development of recombinant human serum albumin. Ther Apher 1998; 2:257-262
106. Sumi A, Okuyama K, Kobayashi K, et al. Purification of recombinant human serum albumin efficient purification using STREAMLINE. Bioseparation 1999; 8:195-200
107. Ohtani W, Nawa Y, Takeshima K, et al. Physicochemical and immunochemical properties of recombinant human serum albumin from Pichia pastoris. Anal Biochem 1998; 256:56-62
108. Dodsworth N, Harris R, Denton K, et al. Comparative studies of recombinant human albumin and human serum albumin derived by blood fractionation. Biotechnol Appl Biochem 1996; 24(Pt 2):171-176
109. Bosse D, Praus M, Kiessling P, et al. Phase I comparability of recombinant human albumin and human serum albumin. J Clin Pharmacol 2005; 45:57-67
110. Kasahara A, Kita K, Tomita E, et al. Repeated administration of recombinant human serum albumin caused no serious allergic reactions in patients with liver cirrhosis: a multicenter clinical study. J Gastroenterol 2008; 43:464-472
111. Ohnishi K, Kawaguchi A, Nakajima S, et al. A comparative pharmacokinetic study of recombinant human serum albumin with plasma-derived human serum albumin in patients with liver cirrhosis. J Clin Pharmacol 2008; 48:203-208
112. Echelard Y, Williams JL, Destrempes MM, et al. Production of recombinant albumin by a herd of cloned transgenic cattle. Transgenic Res 2009; 18:361-376
113. Lee SJ, Chinen J, Kavanaugh A: Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins. J Allergy Clin Immunol 2010; 125:S314-S323
114. Maddur MS, Othy S, Hegde P, et al. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol 2010; 30(Suppl 1):S4-S8
115. Toubi E, Etzioni A: Intravenous immunoglobulin in immunodeficiency states: state of the art. Clin Rev Allergy Immunol 2005; 29:167-172
116. Kivity S, Katz U, Daniel N, et al. Evidence for the use of intravenous immunoglobulins-a review of the literature. Clin Rev Allergy Immunol 2010; 38:201-269
117. Bayry J, Lacroix-Desmazes S, Kaveri SV: Novel therapeutic strategies for multiple sclerosis: potential of intravenous immunoglobulin. Nat Rev Drug Discov 2009; 8:594
118. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, et al. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol 2007; 3:262-272
119. Nimmerjahn F, Ravetch JV: Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26:513-533
120. de Kruif J, Bakker AB, Marissen WE, et al. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 2007; 58:359-368
121. Dodel R, Neff F, Noelker C, et al. Intravenous immunoglobulins as a treatment for Alzheimer's disease rationale and current evidence. Drugs 2010; 70:513-528
122. Radosevich M, Burnouf T: Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang 2010; 98:12-28
123. Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9:325-338
124. Chames P, Van Regenmortel M, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009; 157:220-233
125. Ryan C, Thrash B, Warren RB, et al. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther 2010; 10:587-604
126. Trebst C, Voss E, Skripuletz T, et al. Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis. Curr Med Chem 2010; 17:640-650
127. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-1028
128. Lim SH, Beers SA, French RR, et al. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010; 95:135-143
129. Saylor C, Dadachova E, Casadevall A: Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009; 27(Suppl 6):G38-G46
130. Reichert JM, Dewitz MC: Anti-infective monoclonal antibodies: perils and promise of development. Nat Rev Drug Discov 2006; 5:191-195
131. Muller T, Dietzschold B, Ertl H, et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 2009; 3:e542
132. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9:363-372
133. Weiner LM: Fully human therapeutic monoclonal antibodies. J Immunother 2006; 29:1-9
134. Lai H, Engle M, Fuchs A, et al. Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc Natl Acad Sci U S A 2010; 107:2419-2424
135. Durocher Y, Butler M: Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol 2009; 20:700-707
136. Tuddenham EGD, Kannicht C, Agerkvist I, et al. From human to humans - introducing the first recombinant human FVIII product produced from a human cell line. Thromb Haemost 2010; 103:4-14
137. Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007; 47:1028-1032
138. Nissim A, Chernajovsky Y: Historical development of monoclonal antibody therapeutics. Handb Exp Pharmacol 2008; 181:3-18